Press Release:
Dendreon Corporation (Nasdaq: DNDN) announced the following data presentations taking place at the American Urological Association’s (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: (for those of us who will be unable to attend the session at AUA in Chicago)
April 28, 2009, 2:20 p.m. CDT-“A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC).” AUA Late-Breaking Science Forum to be held from 1:00 p.m. to 2:30 p.m. CDT. Room W375 at McCormick Place
*
April 28, 2009, 10:30 a.m. to 12:30 p.m. CDT-Abstract #1408: “Preclinical Evaluation of the TRPM8 Ion Channel Agonist D-3263 for Benign Prostatic Hyperplasia.” Poster presentation to occur in the Benign Prostatic Hyperplasia: Basic Research session. Room W375B at McCormick Place
*
April 28, 2009, 4:30 p.m. CDT- IMPACT data webcast conference call
The IMPACT (Immunotherapy for Prostate AdenoCarcinoma Treatment) study evaluated PROVENGE® (sipuleucel-T), Dendreon’s investigational product candidate for men with advanced prostate cancer representing the first in a new class of active cellular immunotherapies specifically designed to engage the patient’s own immune system